Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Traders have taken a downbeat view of Cognition Therapeutics’ prospects, with top-line results from a Phase II trial shaking confidence in the firm’s Alzheimer’s research. 29 June 2023
A new Pompe disease therapy has been approved by the European Medicines Agency, with Amicus Therapeutics picking up authorization for the enzyme stabilizer Opfolda (miglustat). 27 June 2023
Shares Avalo Therapeutics plummeted almost 89% to $0.50 by close of trading yesterday, after the US clinical-stage biotech released disappointing clinical trial results asthma candidate. 27 June 2023
US traded shares of Swiss biotech MoonLake Immunotherapeutics leapt almost 79% to $46.58 this morning, after the inflammatory diseases specialist announced positive top-line results from its global Phase II MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS). 26 June 2023
A reminder has been issued of the potential of US biopharma 89bio’s pegozafermin to finally provide a solution in non-alcoholic steatohepatitis (NASH). 26 June 2023
Based on analysis of available information and input from a MEDACorp patent attorney, SVB Securities Research believes US pharma major AbbVie’s allegations that Brukinsa infringes on a recently granted patent (#11,672,803) are substantiative and could potentially result in damages to China-headquartered biotech BeiGene. 26 June 2023
UK cancer immunotherapy firm Immodulon has appointed Richard Couch as chief technology officer and Owen Vaughan as chief regulatory officer. 26 June 2023
Nobody can say that US biopharma Intercept Pharmaceuticals has not done all it can to reach market with a long-awaited treatment for non-alcoholic steatohepatitis (NASH). 23 June 2023
The contract research organization (CRO) IRBM has signed a new agreement with Merck & Co to continue their collaboration in the peptide therapeutics area. 23 June 2023
Switzerland-headquartered Roivant Sciences saw its shares rise 17% in pre-market trading yesterday, after it announced positive results from the chronic period of the TUSCANY-2 Phase IIb study of RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody. 23 June 2023
Shares of US cell therapy developer Talaris Therapeutics leapt 26% to $2.77 this morning, as the company announced a proposed reverse merger. 22 June 2023
Aeglea BioTherapeutics has acquired Spyre Therapeutics, a privately-held biotech advancing antibody therapeutics aimed at transforming the treatment of inflammatory bowel disease (IBD). 22 June 2023
Boston Pharmaceuticals has released positive Phase IIa results for BOS-580, its investigational, proprietary, long-acting fibroblast growth factor 21 (FGF21) analog for the treatment of non-alcoholic steatohepatitis (NASH). 22 June 2023
Promising clinical results from the 12-week portion of the PIVOT-HD Phase II study of PTC518 in Huntington's disease (HD) lifted US pharma group PTC Therapeutics. 22 June 2023
Belgo-Dutch autoimmune diseases specialist argenx can now boast that it has the first subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) to be approved by the US Food and Drug Administration (FDA). 21 June 2023
Adcendo, a Danish biotech focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has appointed Lone Ottesen its chief medical officer (CMO). 20 June 2023
The US Food and Drug Administration (FDA) has slapped a clinical hold on US biotech Arcellx’ CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). 20 June 2023
The appointment of a new chief executive at immune-mediated disease specialist Veralox Therapeutics coincides with a fresh investment of $24 million from new and existing backers. 20 June 2023